4th How to Diagnose and Treat
CML/MPN
March 7-9, 2025 – Vienna, Austria
Chairs: Claire Harrison (London), Andreas Hochhaus (Jena), Ruben Mesa (Winston Salem)

Friday, March 7, 2025

08:45-08:55	**Welcome**	Conference Chairpersons
08:55-09:35	**Keynote lecture** **Chairs: Conference Chairpersons**	
08:55-09:25	Quality of life assessment in hematological diseases	Fabio Efficace (Rome)
09:25-09:35	Discussion	
09:35-09:55	***Coffee Break***	

SESSION I – MPN - ABC of standard care
Chair: Martin Griesshammer (Minden)

09:55-10:15	Case-based lecture Management of ET one disease or more	Anna Godfrey (Cambridge)
10:15-10:20	*Discussion*	
10:20-10:40	Case-based lecture Do we treat low risk PV?	Tiziano Barbui (Bergamo)
10:40-10:45	*Discussion*	
10:45-11:05	Case-based lecture Diagnosis and management of eosinophilia	Andreas Reiter (Mannheim)
11:05-11:10	*Discussion*	
11:10-11:30	Case-based lecture Prognostication in myelofibrosis	Paola Guglielmelli (Florence)
11:30-11:35	*Discussion*	
11:35-11:40	Brief Oral Communication Redefining prognosis in patients with KIT D816V positive advanced systemic mastocytosis on KIT inhibitors	Johannes Lübke (Mannheim)
11:40-11:43	*Discussion*	
11:43-12:05	*Panel discussion*	
12:05-14:00	***Lunch***	

12:50-13:50 **SATELLITE SYMPOSIUM**
Combination therapy in myelofibrosis: Present and future perspectives
Chair: Francesco Passamonti (Milan)
Speakers: Jennifer O'Sullivan (London), Michael Loschi (Nice)
This symposium is organised and supported by Menarini/Stemline

SESSION II – CML - Risk assessment
Chair: Tim Hughes (Adelaide)

14:00-14:20	Case-based lecture Cytogenetic and molecular risk, evolution of standards	Katerina Machova (Prague)
14:20-14:25	*Discussion*	
14:25-14:45	Case-based lecture Role of therapeutic milestones	Dragana Milojkovic (London)
14:45-14:50	*Discussion*	
14:50-15:10	Case-based lecture Prediction of long term TFR	François-Xavier Mahon (Bordeaux)
15:10-15:15	*Discussion*	
15:15-15:22	Interactive case Treatment decision in third line	Delphine Rea (Paris)
15:22-15:25	*Discussion*	
15:25-15:30	Brief Oral Communication ASC4OPT primary analysis reveals high efficacy and favorable tolerability of asciminib at different doses in patients with chronic phase chronic myelogenous leukemia pretreated with 2 or more tyrosine kinase inhibitors	Philipp Le Coutre (Berlin)
15:30-15:33	*Discussion*	
15:33-15:55	*Panel discussion*	

15:55-16:35 **DEBATE 1 – CML - Asciminib first line?**
Chair: Andreas Hochhaus (Jena)

Audience votes

15:55-16:10	Yes	Tim Hughes (Adelaide)
16:10-16:25	No	Giuseppe Saglio (Turin)
16:25-16:35	*Discussion*	

Audience votes again

16:35-17:05 ***Coffee break***

17:05-18:00 ROUNDTABLE 1 – MPN - Challenging clinical scenarios
Chair: Anna Godfrey (Cambridge)

17:05-17:20	Pregnancy	Martin Griesshammer (Minden)
17:20-17:35	Management of fatigue in MPN	Claire Woodley (London)
17:35-17:45	*Discussion*	

17:45-18:40 ROUNDTABLE 2 – CML - Challenging clinical scenarios
Chair: Andreas Hochhaus (Jena)

17:45-18:00	Recurrent cytopenias	Mhairi Copland (Glasgow)
18:00-18:15	Failure to achieve MR2 with 3 TKI	Valentin Garcia-Gutierrez (Madrid)
18:15-18:30	CML in pregnancy	Elisabetta Abruzzese (Rome)
18:30-18:40	*Discussion*	

18:50-20:20 ***Poster Walk and Welcome Get Together stand-up buffet***
Poster Walk leaders: Anna Godfrey (Cambridge), Thomas Ernst (Jena)
Delphine Rea (Paris), Andreas Reiter (Mannheim)

Saturday, March 8, 2025

07:45-08:45 Simultaneous Meet the Expert sessions

1. **Optimization of TFR** — Susanne Saussele (Mannheim)
2. **Management of Myelofibrosis** — Andrew Kuykendall (Tampa)
3. **Management of side effects of MPN drugs** — Francesco Passamonti (Milan)

08:55-09:55 SATELLITE SYMPOSIUM
Navigating the therapeutic landscape: Ongoing challenges and unresolved issues in CML and MPN
Chair: Dragana Milojkovic (London)
Speakers: Delphine Rea (Paris), Haifa Al-Ali (Halle), Barbara Mora (Milan)
This symposium is organised and supported by Novartis

09:55-10:15 Coffee Break

SESSION III – CML & MPN - Long term complications
Chair: David Ross (Adelaide)

10:15-10:35	Case-based lecture Prevention of pleural and pericardial effusions by intermittent dasatinib therapy	Andreas Hochhaus (Jena)
10:35-10:40	*Discussion*	

10:40-11:00	Case-based lecture Blast phase risk and management	Adam Mead (Oxford)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture Management of MPN and CML according to vascular risk	Philipp Le Coutre (Berlin)
11:25-11:30	*Discussion*	
11:30-11:37	Interactive case Anaemia in MF	Ruben Mesa (Winston Salem)
11:37-11:40	*Discussion*	
11:40-11:45	Brief Oral Communication Efficacy of Pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia	Pankit Vachhani (Birmingham)
11:45-11:48	*Discussion*	
11:48-12:10	*Panel discussion*	

12:10-12:50 DEBATE 2 – MPN
Chair: Adam Mead (Oxford)

Audience votes

12:10-12:25	Trial endpoints retain traditional - blood counts, spleen symptoms	Andrew Kuykendall (Tampa)
12:25-12:40	Novel endpoints replace traditional	David Ross (Adelaide)
12:40-12:50	*Discussion*	

Audience votes again

12:50-14:45 Lunch

13:35-14:35 **SATELLITE SYMPOSIUM**
Expert Perspectives: Optimizing treatment of anemia in myelofibrosis
Chairs: Haifa Kathrin Al-Ali (Halle), Veronika Buxhofer-Ausch (Linz)
Speakers: Stefan Wickenhauser (Nimes), Valentin Garcia-Gutierrez (Madrid)
This symposium is organised and supported by BMS

SESSION IV – MPN Management
Chair: Danijela Lekovic (Belgrade)

14:45-14:52	Interactive case Management of indolent SM	Deepti Radia (London)
14:52-14:55	*Discussion*	
14:55-15:15	Case-based lecture Chronic myelomonocytic leukaemia	Daniel Wiseman (Manchester)
15:15-15:20	*Discussion*	

15:20-15:40 Case-based lecture — Claire Harrison (London)
Combination Trials in MF
15:40-15:45 *Discussion*

15:45-16:05 Case-based lecture — Jean-Jacques Kiladjian (Paris)
What do we know regarding IFN in 2025?
16:05-16:10 *Discussion*

16:10-16:15 Brief Oral Communication — Werner Zinkand (Munich)
A Global Survey of MPN Patients' Needs
16:15-16:18 *Discussion*

16:18-16:40 *Panel discussion*

16:40-17:10 Coffee break

SESSION V – CML - Treatment optimization
Chair: Delphine Rea (Paris)

17:10-17:30 Case-based lecture — Tim Brümmendorf (Aachen)
Dose modification
17:30-17:35 *Discussion*

17:35-17:55 Case-based lecture — Thomas Ernst (Jena)
Combination therapies
17:55-18:00 *Discussion*

18:00-18:20 Case-based lecture — Fausto Castagnetti (Bologna)
Symptomatic support / Quality of life
18:20-18:25 *Discussion*

18:25-18:32 Interactive case — Daniela Zackova (Brno)
Dose reduction of TKI for TFR
18:32-18:35 *Discussion*

18:35-18:40 Brief Oral Communication — Jorge Cortes (Augusta)
Asciminib (ASC) continues to provide superior efficacy and favorable safety/tolerability vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in the ASC4FIRST study: week-96 update
18:40-11:43 *Discussion*

18:43-19:05 Panel discussion

Sunday, March 9, 2025

07:45-08:45 Simultaneous Breakfast Meet the Expert Sessions

1. **Management of young MPN patients** — Jean-Jacques Kiladjian (Paris)
2. **Management of newly diagnosed CML** — Jorge Cortes (Augusta)
3. **Management of side effects of CML drugs** — Tim Brümmendorf (Aachen)

08:55-09:55 **SATELLITE SYMPOSIUM**
Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes
Chair: Jean-Jacques Kiladjian (Paris)
Speakers: Paola Guglielmelli (Florence), Francesco Passamonti (Milan)
This symposium is organised by SES-MPNHub and supported by GSK

09:55-10:15 ***Coffee break***

SESSION VI – CML & MPN - What is on the horizon?
Chair: Claire Harrison (London)

10:15-10:35	Case-based Lecture Feedback from ASH in MPN	Francesco Passamonti (Milan)
10:35-10:40	*Discussion*	
10:40-11:00	Case-based lecture Feedback from ASH in CML	Massimo Breccia (Rome)
11:00-11:05	*Discussion*	
11:05-11:25	Case-based lecture Drugs in early development	Jorge Cortes (Augusta)
11:25-11:30	*Discussion*	
11:30-11:50	Case-based lecture Impact of artificial intelligence	Torsten Haferlach (Munich)
11:50-11:55	*Discussion*	
11:55-12:00	Brief Oral Communication Preliminary data from phase I/II study of Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical response strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis	Firas El Chaer (Charlottesville)
12:00-12:03	*Discussion*	

12:03-12:25 *Panel discussion*

12:25-13:00 **Keynote lecture**
Chair: Ruben Mesa (Winston Salem)

12:25-12:55	Modeling the structure of tyrosine kinases and its therapeutic impact	Oliver Hantschel (Marburg)
12:55-13:05	Discussion	

13:05-13:15 ***Closing remarks*** Conference Chairpersons

MEETING CLOSURE